SuperworthMedpace EPS MEDP
Diluted earnings per share by quarter and over the last twelve months, from 2015.
- Last 12 months, to Jun 30, 2026
- $17.05
- Latest quarter, Q2 FY26
- $4.25
- +37% on a year earlier
- Fiscal year 2025
- $15.29
- +21% on the year before
Medpace's earnings per share was $17.05 over the twelve months to Jun 30, 2026, up 27% on a year earlier.
In its latest quarter, Q2 FY26, it was $4.25, up 37% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 32% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $15.29 | +21% |
| FY2024 | $12.63 | +42% |
| FY2023 | $8.88 | +21% |
| FY2022 | $7.32 | +52% |
| FY2021 | $4.81 | +26% |
| FY2020 | $3.83 | +45% |
| FY2019 | $2.65 | +34% |
| FY2018 | $1.98 | +102% |
| FY2017 | $0.98 | +151% |
| FY2016 | $0.39 | n/a |
| FY2015 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $4.25 | +37% | $17.05 | |
| Q1 FY26 | $4.28 | +17% | $15.90 | |
| Q4 FY25 | $4.66 | +27% | $15.29 | |
| Q3 FY25 | $3.86 | +28% | $14.30 | |
| Q2 FY25 | $3.10 | +13% | $13.45 | |
| Q1 FY25 | $3.67 | +15% | $13.10 | |
| Q4 FY24 | $3.67 | +49% | $12.63 | |
| Q3 FY24 | $3.01 | +36% | $11.42 | |
| Q2 FY24 | $2.75 | +42% | $10.63 | |
| Q1 FY24 | $3.20 | +41% | $9.81 | |
| Q4 FY23 | $2.46 | +16% | $8.88 | |
| Q3 FY23 | $2.22 | +8% | $8.54 |
Against its peers
Companies in Medical - Diagnostics & Research nearest Medpace's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MEDPMedpace | $17.05 | +27% a year |
| RVTYRevvity | $2.10 | −11% a year |
| LHLabcorp | $12.09 | +33% a year |
| DGXQuest Diagnostics | $9.41 | +18% a year |
| MTDMettler-Toledo International | $44.42 | +12% a year |
| BIOBio-Rad Laboratories | $8.25 | −30% a year |
| CAICaris Life Sciences | $0.37 | |
| ILMNIllumina | $5.38 | −32% a year |
| IDXXIDEXX Laboratories | $14.22 | +18% a year |
| WATWaters | $4.01 | −64% a year |
| IQVIQVIA | $8.06 | +17% a year |
| Peer median | $8.15 |
Where Medpace ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Medpace
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.